Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy by Hintringer, K.
  
Horizon Scanning in 
Oncology 
Romidepsin (Istodax®) for the 
treatment of patients with 
relapsed or refractory peripheral 
T-cell lymphoma (PTCL) after 
prior systemic therapy 
 
 
 
DSD: Horizon Scanning in Oncology Nr. 025
ISSN online 2076-5940

  
Horizon Scanning in 
Oncology 
Romidepsin (Istodax®) for the 
treatment of patients with 
relapsed or refractory peripheral 
T-cell lymphoma (PTCL) after 
prior systemic therapy 
 
 
 
Vienna, April 2012 
Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft  
 
Author(s):   Katharina Hintringer, BA 
Internal review:   Dr. Anna Nachtnebel, MSc 
External review:  Prim. Univ. Doz. Dr. Michael A. Fridrik 
    Innere Medizin 3, Zentrum fu¨r Ha¨matologie und 
    medizinische Onkologie 
    AKH Linz 
 
 
 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited 
literature search. It is not a definitive statement on safety, effectiveness or efficacy and cannot re-
place professional medical advice nor should it be used for commercial purposes. 
 
CONTACT INFORMATION
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nussdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institute of Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize 
the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
“http://eprints.hta.lbg.ac.at”: 
DSD: Horizon Scanning in Oncology Nr. 025 
ISSN online 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/dsd.html 
© 2012 LBI-HTA – All rights reserved
 LBI-HTA | 2012 3 
1 Drug description 
Generic/Brand name/ATC code:  
Romidepsin, (formerly referred to as depsipeptide, FK228) / Istodax ® / 
ATC code not yet assigned 
Developer/Company:  
Celgene Corporation, USA 
Description: 
Romidepsin is a histone deacetylase inhibitor (HDI) with high inhibitory 
activity for class I histone deacetylases (HDACs). Currently, HDIs (e.g. 
vorinostat, romidepsin) are a promising class of chemotherapeutic agents in 
T-cell lymphomas but their exact mechanism by which their anti-tumour ac-
tivity is mediated is not yet fully understood [1-4]. Descriptions of the 
mechanisms of action of romidepsin suggest that it leads to various antineo-
plastic effects including cell-cycle arrest and apoptosis by inhibiting the 
HDAC enzyme, induction of autophagy, reactive oxygen species generation, 
Hsp90 inhibition and disruption of the aggresome pathway [1, 3, 5]. 
Romidepsin is approved at a dose of 14mg/m² as a 4-hour intravenous infu-
sion on days 1, 8 and 15 of a 28-day cycle for the treatment of patients suffer-
ing from cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lym-
phoma (PTCL) [6-8]. Temporary delays, temporary or permanent dosage 
reduction to 10mg/m² or discontinuation of romidepsin may be necessary, 
depending on each individual patient’s response and tolerability [1]. One 
trial in PTCL [9] and one in CTCL [10] limited the number of treatment 
cycles to a maximum of 6 with the option of extension for patients with sta-
ble disease or response [9, 10]. The US Food and Drug Administration (US 
FDA) recommends to repeat the treatment cycle every 28 days provided the 
patient continues to benefit from and tolerates the drug [11]. Currently no 
contraindications are listed for romidepsin. The most common and most se-
vere adverse events observed with romidepsin are leucopoenia, lym-
phopenia, granulocytopenia, thrombocytopenia, fatigue and anaemia [1] and 
therefore, close monitoring of hematologic parameters is recommended in 
order to adjust the dosage of romidepsin if necessary [11]. 
2 Indication 
Romidepsin (Istodax®) is indicated for the treatment of patients with re-
lapsed or refractory peripheral T-cell lymphoma (nodal, extranodal or leu-
kemic/disseminated) after prior systemic therapy. 
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3 Current regulatory status 
In 2005, the European Medicines Agency (EMA) granted orphan drug des-
ignation for romidepsin (formerly depsipeptide) for the treatment of CTCL 
[12] and PTCL (nodal, extranodal and leukemic/disseminated) [13]. Ro-
midepsin is not yet approved for any of these two indications in Europe, but 
is currently under authorisation review for the treatment of PTCL. In addi-
tion, a product-specific waiver was granted by the paediatric committee for 
this indication [14]. The Paediatric Committee of the EMA can waive the 
requirement to submit a paediatric investigation plan with the marketing 
authorisation application if the medicinal product a) is likely to be ineffec-
tive or unsafe in part or all of the paediatric population, b) is intended for 
indications that occur only in adult populations or c) does not represent a 
significant therapeutic benefit over existing treatment for paediatric pa-
tients [15]. 
In 2004, the US Food and Drug Administration (FDA) issued an orphan 
drug designation for romidepsin for the treatment of non-Hodgkin’s T-cell 
lymphomas, which includes CTCL and PTCL [16]. In November 2009, the 
FDA approved romidepsin for the treatment of CTCL in patients who have 
received at least one prior systemic therapy and extended the approved indi-
cation in June 2011 for the treatment of PTCL also to patients who have re-
ceived at least one prior therapy [11]. The approval for both indications was 
issued in the fast track programme, which allows companies to submit mod-
ules of a new drug application (NDA) on an ongoing basis for a “rolling re-
view” by the FDA as soon as the modules are submitted [17].  
4 Burden of disease 
T-cell lymphomas belong to Non-Hodgkin’s lymphomas (NHL), a heteroge-
neous group of lymphoproliferative disorders, and originate in T-cells (10-
15%) [7]. Two of the most common subsets of T-cell lymphomas are cutane-
ous T-cell lymphomas (CTCL) and peripheral T-cell lymphomas (PTCL). 
About 5% to 10% of all NHLs are PTCLs [18-20]. PTCL arises from post-
thymic T-cells at various stages of differentiation, and may be leukemic, 
nodal (i.e. lymphoma arises in lymph nodes or other lymphatic tissues such 
as the spleen) or extranodal (i.e., substantial part of NHL arises in other or-
gans e.g., skin and gastrointestinal tract) in nature. The latter three form the 
basis of the World Health Organisation (WHO) classification of PTCL [21, 
22].  
The most common types of PTCL include  
 PTCL-not otherwise specified or unspecified (PTCL NOS, 25.9%), 
 angioimmunoblastic T-cell lymphoma (AILT, 18.5%)  
 natural killer/T-cell lymphomas (NKTCL, 10.4%) 
 adult T-cell leukaemia/lymphoma (ATLL, 9.6%)  
 anaplastic large-cell lymphoma (ALCL), which can be further distin-
guished into anaplastic lymphoma kinase (ALK) positive (ALCL 
ALK-positive; 6.6%) and ALCL ALK-negative (5.5%) [1, 23].  
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With regard to the different sub-types of PTCL there is geographical varia-
tion in the frequency of occurrence. In Europe, PTCL-NOS, ALCL and 
AITL account for about 75% of all PTCL cases [13]. Under PTCL-NOS a 
heterogeneous category of nodal and extranodal lymphomas are summarised 
that cannot be grouped into other more specifically defined T-cell lympho-
mas [24]. Because of the rarity and diversity of PTCLs, biology of the disease 
and definition of the optimal treatment is not well understood and devel-
oped [14]. PTCL is clinically highly variable, but in general very aggressive 
and does therefore not respond well to conventional chemotherapy; with ex-
ception of ALK-positive ALCL [1]. 
The median age at time of diagnosis over all subtypes is around 60 years 
with a range from 17 to 90 years [13, 25], with men being more often affected 
than women (2:1) [11]. The SEER (Surveillance, Epidemiology, and End Re-
sults) data in the US reports an incidence of 1.77/100,000 per year for T-cell 
and NK-cell lymphoma. Most PTCL patients present extranodal disease at 
time of diagnosis, which often contributes to a delay in diagnosis. Subse-
quently patients tend to present with more advanced stages of disease, a 
poorer performance status and an increased incidence of B-symptoms such 
as fever, weight loss and night sweats [13, 21]. Approximately 14%, 17%, 
26% and 43% of cases are at stage I, II, III or IV, respectively, and bone mar-
row is involved in about 20% of patients at time of diagnosis [11]. 
PTCL is diagnosed by using various tests (e.g. examination of the peripheral 
blood or tissue biopsy for histological features supplemented by detailed 
immunochemistry, flow cytometry, cytogenetics and molecular genetics) by 
an expert haematology review in order to classify the presenting subtype 
correctly. Further, staging of the disease and subsequently assigning a prog-
nostic score is essential for determining the therapeutic treatment manage-
ment process [13]. Currently, the causes of T-cell lymphoma are not exactly 
known and most people diagnosed, have no known risk factors. One assump-
tion is that certain infections may play an important role in caus-
ing/developing selected types of NHL [25].  
Overall, PTCL is associated with a poor prognosis with a median 5-year 
overall survival (OS) rate of ~35%; except for the ALK-positive ALCL, 
which is associated with a better prognosis and a 5-year OS rate of around 
70% [7, 14]. 
Based on the Ann Arbor staging classification for Hodgkin lymphoma (HL) 
and NHL four disease stages (stage I, II, III and IV) can be discriminated. 
Staging of the disease depends on the area(s) involved (i.e. stage I is attrib-
uted to NHL with a single lymph node group involved and stage IV disease 
is defined as the involvement of multiple extranodal sites or lymph nodes 
and extranodal sites) [23]. Additionally, different sub-classifications are 
added to describe the characteristics of the disease in more detail. For ex-
ample the letters A and B are added for the absence (A) or presence (B) of B 
symptoms (i.e., fever >38°C, night sweat, weight loss >10% over 6 months) 
[4, 9], the letter X is added when the tumour bulk is >10 cm and E indicates 
extranodal disease [23]. The Ann Arbor classification was originally devel-
oped for HL. As HL and NHL spread differently, the Ann Arbor classifica-
tion is less accurate for NHL patients and thus, new predictive models were 
developed [26]. 
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treatment are not fully 
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Two prognostic models are widely used in T-cell lymphomas. The Interna-
tional Prognostic Index (IPI) was originally developed for diffuse large B-
cell lymphomas, successfully separating patients with PTCL-NOS and 
ALCL into distinct prognostic categories. However, it has limited applica-
bility in other subtypes of peripheral T-cell lymphoma. In 2004, Gallamini 
et al. developed another prognostic model for PTCL-NOS, which takes ad-
vanced age (>60 years), poor performance status (≥2), increased lactate de-
hydrogenase (LDH) (≥upper limit of normal (ULN)) and marrow infiltra-
tion into account [24]. 
After initial therapy patients are monitored regularly in order to confirm re-
sponse, remission or relapsed/refractory disease. Unfortunately, most pa-
tients will not achieve remission or will relapse. Progressive disease gener-
ally presents with B symptoms and should be confirmed by biopsy of the in-
volved lymph node or mass and evaluation for a potential change in histol-
ogy (e.g. patient with PTCL can develop B-cell lymphoma at the time of re-
lapse). Patients refractory or resistant to initial therapy are defined as those 
who fail to obtain an at least partial response determined as at least 50% de-
crease in lesion size with no new lesions [9]. 
In 2009, 1,225 (8 per 100,000 habitants) patients were newly diagnosed with 
NHL in Austria. Men were more often affected than women (men: 577 vs 
women: 548; 9.5 vs. 6.7 per 100,000 habitants, respectively) [27]. Applying 
the above mentioned estimates approximately 60 to 120 patients are newly 
diagnosed with T-cell lymphoma per year in Austria. 
5 Current treatment 
Prior to treatment initiation the precise histological subtype, the extent and 
sites of disease and the performance status of a patient have to be deter-
mined [28]. No consensus on the preferred first-line therapy in PTCL exists, 
but patients are encouraged whenever possible to enrol onto clinical trials. 
For patients who are not eligible, who do not have the possibility or who do 
not want to enrol in a clinical trial the selection of therapy should be based 
on expected toxicities, patient co-morbidities and convenience. The most 
common chemotherapy regimens are CHOP or EPOCH: 
 CHOP includes cyclophosphamide, doxorubicin, vincristine and 
prednisone (CHOEP - with etoposide) 
 EPOCH includes etoposide, prednisone, vincristine, cyclophos-
phamide, doxorubicin. 
Though the role of consolidation therapy with autologous hematopoietic 
stem cell transplantation (HSCT) or radiation therapy is discussed contro-
versially, it might be a feasible option in certain PTCL subgroups where pa-
tients have poor outcomes after conventional therapy [9]. 
Those patients who relapse after or are resistant to initial therapy generally 
receive a second-line combination therapy aiming to achieve a complete re-
mission (CR). Responders are then eligible for autologous or allogeneic 
HSCT. The advantage of HSCT is the potential for long-term disease-free 
survival in comparison to chemotherapy alone [9, 23]. 
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Novel agents for the treatment of PTCL are currently recommended only af-
ter relapses following initial chemotherapy due to higher response rates ob-
served with traditional chemotherapy and the chance of the patients to 
achieve long-term survival when eligible for HSCT after response to chemo-
therapy [9]. 
For patients eligible for HSCT the following therapy regimens, originally 
developed for aggressive lymphoma are available: 
 ICE (ifosfamide, carboplatin and etoposide) 
 DHAP (dexamethasone, high dose cytarabine and cisplatin) 
 ESHAP (etoposide, methyl-prednisolone, cytarabine and cisplatin) 
 Single agent gemcitabine 
 Gemcitabine, cisplatin and dexamethasone 
 Gemcitabine and oxaliplatin [9].  
Patients with PTCL were included in these trials for aggressive lymphomas. 
Due to the small sample size of PTCL patients the impact of each chemo-
therapy regimen on PTCL could not be assessed. Up to now, there are no 
randomized studies comparing chemotherapy exclusively in PTCL [9, 19]. 
For patients unresponsive to therapy, best supportive care with the primary 
aim of symptomatic relief and palliation is indicated [19, 23]. 
6 Evidence 
A literature search was conducted on February 10th, 2012 in four databases 
(Cochrane Library, EMBASE, Ovid, and CRD Database) yielding 148 refer-
ences overall. In addition a hand search was performed including the web-
sites of the EMA and the US FDA. 
Within the efficacy and safety chapter of this report only studies which en-
rolled patients with relapsed or refractory PTCL after at least one prior sys-
temic therapy were considered. This resulted in the inclusion of 2 single-arm 
phase II studies. 
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6.1 Efficacy and safety – pivotal studies 
Table 1 Summary of efficacy of study NCT00426764 
Study title  
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell 
lymphoma after a prior systemic therapy [20] 
Study identifier NCT00426764 (formerly registered as NCT00924378); EudraCT Number: 2006-006228-
21; GPI-06-0002 
Prospective, single-arm, phase II trial in 48 sites in Europe, Australia and United States Design 
Duration  Enrolment: NA 
Median follow-up: NA 
Cut-off date for final analysis: October 31, 2010 
Hypothesis Single-arm study 
Funding Celgene 
Intervention Romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8 
and 15 of each 28-day cycle for up to six cycles 
patients with stable disease (SD), partial response (PR), or complete 
response (CR)/ unconfirmed CR (CRu) could elect to extend therapy 
until progressive disease (PD) or another withdrawal criterion was 
met 
Treatment 
groups 
Control - 
Endpoints and 
definitions 
Complete response 
or unconfirmed 
complete response  
(primary outcome) 
CR or 
CRu 
Disease response was assessed every two cycles by individual 
site investigators and an independent review committee 
(IRC) by using the IWC guidelines [29] for response assess-
ment for non-Hodgkin’s lymphoma. 
CR requires: 
1. complete disappearance of all detectable clinical and radio-
graphic evidence of disease and disappearance of all disease-
related symptoms if present before therapy, and normaliza-
tion of those biochemical abnormalities (e.g., LDH) definitely 
assignable to NHL, 
2. all lymph nodes and nodal masses must have regressed to 
normal size, 
3. the spleen, if considered to be enlarged before therapy on 
the basis of a CT scan, must have regressed in size und must 
not be palpable on physical examination, 
4. if bone marrow was involved by lymphoma before treat-
ment, the infiltrate must be cleared on repeat bone marrow 
aspirate and biopsy of the same site. 
 
CRu includes those patients who fulfil criteria 1 and 3 above, 
but with one or more of the following features: 
1. a residual lymph node mass greater than 1.5 cm in greatest 
transverse diameter that has regressed by more than 75% in 
the sum of the products of the greatest diameters (SPD). In-
dividual nodes that were previously confluent must have re-
gressed by more than 75% in their SPD compared with the 
size of the original mass, 
2. indeterminate bone marrow (increased number or size of 
aggregates without cytologic or architectural atypia) [29]. 
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Partial response PR PR is defined as: 
1. ≥50% decrease in SPD of the six largest dominant nodes or 
nodal masses, 
2. no increase in the size of the other nodes, liver, or spleen, 
3. splenic and hepatic nodules must regress by at least 50% in 
the SPD, 
4. with the exception of splenic and hepatic nodules, in-
volvement of other organs is considered assessable and not 
measurable disease, 
5. bone marrow assessment is irrelevant for determination of 
a PR because it is assessable and not measurable disease, 
6. no new sites of the disease [29]. 
Objective response 
rate 
ORR CR/Cru + PR 
Duration of re-
sponse 
DOR Time from the first date of a response to the date of PD or 
date of last study assessment 
Time to objective 
disease progression 
- Time from the first infusion to the date of PD or last disease 
assessment 
Change in ECOG PS - Not specified 
Progression-free 
survival 
PFS Time from the first infusion to the date of PD, last study as-
sessment, or death 
Stable disease SD No definition provided. 
Progressive disease PD Time from the first infusion to the date of PD or last disease 
assessment. 
Results and analysis 
Analysis  
description 
Time-to-event data were summarized by using Kaplan-Meier methods 
Analysis  
population 
Characteristics Median age: 61 years (range 20 to 83) 
Sex: 32% females; 68% males 
White race/ethnicity: 89% 
ECOG PS 0/1/2: 35%/51%/13% 
IPI <2/≥2: 24%/76% 
Median time since diagnosis: 1.3 years (range 0.2 to 17.0) 
Most common PTCL subtypes (≥5%) 
PTCL NOS: 53% 
Angioimmunoblastic T-cell lymphoma: 21% 
ALK-1-negative ALCL: 16% 
Enteropathy-type T-cell lymphoma: 5% 
Type of prior systemic therapy (chemotherapy/ monoclonal an-
tibody therapy/ other type of immunotherapy): 99%/15%/11% 
Number of prior systemic therapies 
Mean (range): 2 (1 to 8) 
1/2/3/4/>4: 29%/34%/15%/12%/11% 
Received prior autologous stem-cell transplantation: 16% 
Refractory to most recent therapy: 38% 
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Inclusion - histological types according to WHO classification: PTCL 
NOS, AITL, extranodal NK/TCL nasal type, enteropathy-type 
TCL, subutaneous panniculitis-like TCL, cutaneous 
gamma/delta TCL, transformed mycois fungoides, hepa-
tosplenic TCL, ALK-1-negative ALCL; ALK-1-positive ALCL pa-
tients were only enrolled if relapsed following ASCT; 
- ≥18 years of age; 
- relapsed or refractory disease to at least one systemic ther-
apy; 
- adequate bone marrow and organ function (haemoglobin 
≥9.0 g/dL, absolute neutrophil count >1.0 x 109/L, platelet 
count ≥100 x 109/L or ≥75 x 109/L if bone marrow involve-
ment was documented);  
- total bilirubin, AST and ALT ≤2 x upper limit of normal 
(ULN) or ≤ 3 x ULN if liver involvement was present; 
- and serum creatinine ≤2 x ULN; 
- measureable disease according to IWC and/or measureable 
cutaneous disease; 
- ECOG PS 0 to 2 
Exclusion - patients who had nontransformed mycosis fungoides or Se´-
zary syndrome, known CNL lymphoma, clinically significant 
active infection, previous extensive radiotherapy, prior ex-
posure to romidepsin, or any known significant cardiac ab-
normalities; 
- use of any investigational agent, chemotherapy or immuno-
therapy within 4 weeks of study entry (within 6 weeks for 
nitrosoureas) was not allowed 
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Treatment group Overall IRC Assessment Investigator’s assessment 
Number of subjects n=130 
ORR, n (%) 
CR/CRu 
CR 
CRu 
PR 
SD 
PD or not evalu-
able 
33 (25) 
19 (15) 
13 (10) 
6 (5) 
14 (11) 
33 (25) 
64 (49) 
38 (29) 
21 (16) 
19 (15) 
2 (2) 
17 (13) 
22 (17) 
70 (54) 
Median time to re-
sponse (n=33), 
months (range) 
All responders 
CR/CRu + PR) 
CR/CRu 
 
 
 
 
1.8 (1.4 to 5.3) 
3.7 (1.6 to 13.7) 
 
 
 
 
1.8 (1.0 to 4.3) 
2.4 (1.6 to 9.6) 
Descriptive sta-
tistics and es-
timated vari-
ability 
Median DOR (n=33), 
months (range) 
All responders 
CR/CRu + PR 
CR/CRu 
 
 
 
16.6 (<0.1 to 34.0) 
16.6 (<0.1 to 34.0) 
 
 
 
11.6 (0.5 to 34.0) 
NA (1.2 to 34.0) 
 Improvement in 
ECOG PS (n=82), % 
CR/CRu 
PR 
SD 
PD or N/E 
 
 
83 
60 
52 
18 
NA 
 Median PFS, months 
Overall 
CR/CRu 
PR 
SD 
PD or N/E 
 
4 
18 
7 
6 
<2 
NA 
Abbreviations: IRC – independent review committee; ECOG PS – Eastern Cooperative Oncology Group per-
formance status; NA – not available; N/E – not evaluable 
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Overall, 131 patients were enrolled in the study. One patient with a diagno-
sis of diffuse large B-cell lymphoma was excluded from the efficacy assess-
ment but included in the safety assessment. The median age of the 130 in-
cluded PTCL patients was 61 years (range 20-83). 13% of patients had an 
ECOG PS 2 at enrolment. The median time since first diagnosis of PTCL 
was 1.3 years (range 0.2 to 17.0). The majority of included patients presented 
with the subtype PTCL NOS (53%). All included patients received prior 
chemotherapy, monoclonal antibody therapy or another type of immuno-
therapy The median number of prior therapies was 2 (range 1-8). 16% re-
ceived prior HSCT and 38% of patients were refractory to prior therapy. 
ORR as assessed by the independent review committee (IRC) was 25% in-
cluding 10% CR, 5% CRu and 11% PR. The median duration of response 
for all responders was the same as for patients with CR/CRu (16.6 months 
(range <0.1 to 34.0). At the time of data cut-off 17 (90%) of 19 patients with 
CR/CRu remained in remission. The median follow-up in these patients was 
13.4 months. According to subgroup-analyses, baseline disease characteris-
tics, prior therapeutic regimens and the number of prior therapies did not 
have an impact on the ability of patients to respond to romidepsin. 
The assessment of the ECOG PS showed improvements in 34 (41%) of 82 
patients for whom baseline and post-baseline PS data were available over the 
course of therapy. 
Table 3 provides an overview of the most commonly observed adverse events 
(AEs). These were nausea, infections (all types), fatigue, thrombocytopenia, 
vomiting and diarrhoea. Generally, most AEs were considered to be mild to 
moderate in severity. The most common grade ≥3 AEs were thrombocyto-
penia, neutropenia and infection of any type. The most common severe AEs 
were infections of all types (19%), pyrexia (7%) and vomiting (5%). 47% of 
patients required at least one dose interruption of romidepsin and 10% re-
quired a dose reduction to 10mg/m² for the management of AEs. The most 
common reasons for dose interruptions were thrombocytopenia (18%), infec-
tions (12%) and neutropenia (11%). As a result of AEs, treatment discon-
tinuation was reported in 19% of the patients and 10% were considered to be 
drug-related. 8 (6%) patients died within 30 days of the last study drug dose 
due to progressive disease (n=3), infection or an event that occurred during 
infection (n=5). One death was reported to be study drug related. 
 
130 patients included for 
efficacy assessment 
 
most common PTCL 
subtypes: PTCL NOS, 
angioimmunoblastic T-
cell lymphoma, ALCL 
ORR: 25% 
median duration of 
ORR: 16.6 months 
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vomiting and diarrhoea 
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30 days after 
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study drug 
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Table 2 Summary of efficacy of study NCT00007345 
Study title  
Depsipeptide to treat patients with cutaneous T-cell lymphoma and peripheral T-cell lymphoma. 
Results in patients with CTCL were previously reported [30] and this analysis is limited to the patients 
with PTCL [7]. 
Study identifier NCT00007345 (formerly: NCT00020436) 
multi-institutional, single-arm phase II study Design 
Duration  Enrolment: NA 
Median follow-up: NA 
Cut-off date for final analysis: February 22, 2010 
Hypothesis single-arm study 
Funding National Institutes of Health, National Cancer Institute, Center for Cancer Research and 
by a Cooperative Research and Development Agreement with Gloucester Pharmaceuti-
cals (and Celgene Corporation).  
Intervention 14mg/m2 romidepsin as a 4-hour intravenous infusion on days 1, 8 
and 15 of a 28-day cycle 
Treatment 
groups 
Control - 
Response assess-
ment (primary 
endpoint) 
 Responses in patients with nodal disease were assessed using 
the IWG guidelines [29]. 
Responses in patients with skin or visceral lesions were as-
sessed using Response Evaluation Criteria in Solid Tumors 
(RECIST) [31]. 
complete response CR CR requires: 
1. complete disappearance of all detectable clinical and radio-
graphic evidence of disease and disappearance of all disease-
related symptoms if present before therapy, and normaliza-
tion of those biochemical abnormalities (e.g., LDH) definitely 
assignable to NHL, 
2. all lymph nodes and nodal masses must have regressed to 
normal size, 
3. the spleen, if considered to be enlarged before therapy on 
the basis of a CT scan, must have regressed in size und must 
not be palpable on physical examination, 
4. if bone marrow was involved by lymphoma before treat-
ment, the infiltrate must be cleared on repeat bone marrow 
aspirate and biopsy of the same site [29]. 
Endpoints and 
definitions 
partial response PR PR is defined as: 
1. ≥50% decrease in SPD of the six largest dominant nodes or 
nodal masses, 
2. no increase in the size of the other nodes, liver, or spleen, 
3. splenic and hepatic nodules must regress by at least 50% in 
the SPD, 
4. with the exception of splenic and hepatic nodules, in-
volvement of other organs is considered assessable and not 
measurable disease, 
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5. bone marrow assessment is irrelevant for determination of 
a PR because it is assessable and not measurable disease, 
6. no new sites of the disease [29]. 
stable disease SD less than PR but not progressive disease 
progressive disease PD ≥50% increase from nadir in the SPD of any previously iden-
tified abnormal node for PRs or non-responders and the ap-
pearance of any new lesion during or at the end of therapy 
Results and analysis 
Analysis  
description 
duration of response was assessed by Kaplan-Meier method 
Characteristics Male vs female, n (%): 25 (53) vs 22 (47) 
Median age, years (range): 59 (27-84) 
ECOG PS 0/1/2, n (%): 20 (43) / 23 (49) / 4 (9) 
Stage II/III/IV disease, n (%): 2 (4) / 11 (24) / 34 (72) 
Median number of prior therapies, n (range): 3 (1-11) 
Type of prior therapy, n (%) (cytotoxic chemotherapy / inter-
feron / bexarotene / experimental and other / stem-cell trans-
plant / radiation therapy): 47 (100) / 3 (6) / 3 (6) / 3 (6) /18 (38) 
/ 19 (40) 
Median number of prior cytotoxic therapies, n (range): 2 (1-6) 
Primary diagnosis, n (%):  
PTCL NOS: 27 (57) 
angioimmunoblastic: 7 (15) 
ALCL, ALK-pos / ALCL, ALK-neg / primary cutaneous 
anaplastic large T-cell / cutaneous γδ T-cell: each 2 (4) 
hepatosplenic PTCL / enteropathy associated T-cell lym-
phoma / PTCL, unspecified of the skin / CD30 lymphoprolif-
erative disorder / diffuse large B-cell lymphoma: each 1 (2) 
Inclusion initially, patients with relapsed or refractory PTCL NOS or pri-
mary cutaneous anaplastic large cell lymphoma who had not re-
ceived more than 2 systemic cytotoxic chemotherapy regimens. 
Trial was amended and other mature T-cell lymphoma subtypes 
and patients who had previously received more than 2 cytotoxic 
therapies 
measurable disease, age ≥18 years, ECOG PS 0 to 2, life expec-
tancy of >12 weeks. 
required laboratory values: absolute neutrophil count (ANC) ≥1 
x 109 cells/L, platelets ≥100 x 109/L, bilirubin ≤1.5 x the institu-
tional ULN, AST ≤3x ULN, and creatinine ≤1.5 x ULN. 
Analysis  
population 
Exclusion CNS involvement, HIV infection or prior therapy with an HDAC 
inhibitor, pregnant women; 
chemotherapy within four weeks prior study entry 
unstable angina, myocardial infarction within the previous 12 
months, left ventricular ejection fraction below normal (<45% if 
performed by MUGA or <50% if performed by echocardiogram 
or cardiac MRI), or corrected QT interval of >480 ms  
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Treatment group  
Number of subjects n = 45 
ORR, n (%) 
CR 
PR 
17 (38) (95% CI 24% to 53%) 
8 (18) 
9 (20) 
SD, n (%) 5 (11) 
PD, n (%) 18 (40) 
Descriptive 
statistics and 
estimated vari-
ability 
median duration of ORR, 
months (range) 
median duration of CR 
median duration of PR 
median duration of SD 
 
8.9 (2 to 74) 
29.7 (3 to 74) 
5.2 (2 to 23+) 
6 (3 to 12) 
 
 
In this pivotal single-arm phase II trial 47 PTCL patients were enrolled. 45 
were considered for efficacy assessment and all included patients were in-
cluded in the safety assessment. The median age of the study population was 
59 years with 23 patients being aged >60 years. The majority of included pa-
tients had an ECOG PS of 0 or 1. The most common subtypes of PTCL were 
PTCL NOS (57%) and angioimmunoblastic T-cell lymphoma (15%). All pa-
tients had received prior cytotoxic chemotherapy with a medium number of 
2 (1-6). Overall, 118 prior cytotoxic regimes were administered to the 47 pa-
tients with the majority being either CHOP (n=32), ICE (n=11) or other 
combination regimens (not specified, n=59). 
Overall, 373 treatment cycles were administered. The median number of 
administered therapies per patient was 3 (range 1 to 57) corresponding to a 
total number of 1,062 administered doses. Of these, 417 doses were reduced 
and among doses reduced, 137 doses were reduced due to toxicity. ORR, the 
primary outcome, was 38% (95% CI, 24% to 53%) consisting of 18% CR and 
20% PR. Median duration of overall response was 8.9 (range 2 to 74) 
months. Median duration of CR and PR was 29.7 (range 3 to 74) and 5.2 (2 
to 23+), respectively. 11% and 40% of patients showed stable disease and 
progressive disease, respectively, while on study. 
The most common AEs of the study NCT00007345 are presented in Table 3. 
The incidence of AEs reported in this study are derived from the highlights 
of prescribing information provided by the US FDA [8] because in the full 
text publication of the NCT00007345 study [7], only AEs after the first cycle 
are presented which were, overall, less frequent and less severe than those 
reported in the FDA document.  
Overall the observed AEs were comparable in terms of frequency and sever-
ity to those in the NCT00426864 trial. Two patients died while on study due 
to progressive disease and as a result of a past cardiac history, whereas 5 
died within 30 days of removal from study due to progressive disease and 
haemophagocytosis syndrome. Even though the patient with cardiac history 
experienced CR on romidepsin, the protocol enrolment criteria were 
amended to exclude patients with significant cardiovascular disease as well 
as other patients at risk for sudden death.  
45 patients considered 
for efficacy assessment 
median age: 59 years 
417 of 1062 doses were 
reduced  
overall ORR: 38% 
median duration of 
ORR: 8.9 months 
most frequent and most 
severe AEs 
2 patients died while on 
study and 5 within 30 
days after last study 
drug dose 
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Table 3 Adverse Reactions Occurring in ≥10% of Patients with PTCL in Study 
NCT00426764 [20] and corresponding Incidence in Study NCT00007345 
[7], derived from the Highlights of Prescribing Information, FDA [8] 
 Study NCT00426764, 
(n=131) 
Study NCT00007345, 
(n=47) 
 
Outcome, n (%) 
All  
Grades 
Grade  
3 or 4 
All  
Grades 
Grade  
3 or 4 
Any adverse reactions, n 
(%) 
127 (97) 86 (66) 47 (100) 40 (85) 
Gastrointestinal disorders 
 Nausea 77 (59) 3 (2) 35 (75) 3 (6) 
 Vomiting 51 (39) 6 (5) 19 (40) 4 (9) 
 Diarrhoea 47 (36) 3 (2) 17 (36) 1 (2) 
 Constipation 39 (30) 1 (1) 19 (40) 1 (2) 
 Abdominal pain 18 (14) 3 (2) 6 (13) 1 (2) 
 Stomatitis 13 (10) 0 3 (6) 0 
General disorders and administration site conditions 
 Asthenia/Fatigue 72 (55) 11 (8) 36 (77) 9 (19) 
 Pyrexia 46 (35) 7 (5) 22 (47) 8 (17) 
 Chills 14 (11) 1 (1) 8 (17) 0 
 Oedema, peripheral 13 (10) 1 (1) 3 (6) 0 
Blood and lymphatic system disorders 
 Thrombocytopenia 53 (41) 32 (24) 34 (72) 17 (36) 
 Neutropenia 39 (30) 26 (20) 31 (66) 22 (47) 
 Anaemia 32 (24) 14 (11) 29 (62) 13 (28) 
 Leucopoenia 16 (12) 8 (6) 26 (55) 21 (45) 
Metabolism and nutrition disorders 
 Anorexia 37 (28) 2 (2) 21 (45) 1 (2) 
 Hypokalaemia 14 (11) 3 (2) 8 (17) 1 (2) 
Nervous system disorders 
 Dysgeusia 27 (21) 0 13 (28) 0 
 Headache 19 (15) 0 16 (34) 1 (2) 
Respiratory, thoracic and mediastinal disorders 
 Cough 23 (18) 0 10 (21) 0 
 Dyspnoea 17 (13) 3 (2) 10 (21) 2 (4) 
Investigations 
 Weight decreased 13 (10) 0 7 (15) 0 
Cardiac disorders 
 Tachycardia 13 (10) 0 0 0 
 LBI-HTA | 2012 17 
Other outcomes 
 Infections SOC* 72 (55) 25 (19)   
 Death (all cause) 
within 30 days of 
last romidepsin dose 
6%  17%  
 Discontinuation due 
to AE 
19%  28%  
Adverse Events according to the National Cancer Institute-Common Terminol-
ogy Criteria for Adverse Events (NCI-CTCAE, Version 3.0);  
Abbreviation: SOC – system organ class (according to Medical Dictionary for 
Regulatory Activities); 
*None of the individual preferred term events in the infections SOC were re-
ported with an incidence of 10% or greater 
 
6.2 Efficacy and safety - further studies 
No further trials of romidepsin for the treatment of PTCL were included.  
7 Estimated costs 
To date, romidepsin is not approved in Europe, therefore, no price estimates 
are available yet in Austria.  
8 Ongoing research 
One on-going phase III study using romidepsin as a comparator in the 
treatment of patients with relapsed or refractory peripheral T-cell lym-
phoma (PTCL) is registered at ClinicalTrials.gov. 
NCT01482962: evaluates the effectiveness of alisernib compared to single-
agent treatment, as selected by the investigator from the offered options of 
pralatrexate, romidepsin (in countries where it is permitted to be used), or 
gemcitabine in patients with relapsed or refractory peripheral T-cell lym-
phoma. This study was initiated in January 2012 and the estimated study 
completion date is April 2017.  
No further phase III trial was identified for this indication on the EU Clini-
cal Trials Register (www.clinicaltrialsregister.eu), but one phase IV, rollover 
study for T-cell lymphoma patients previously already recruited in a ro-
midepsin trial is ongoing.  
No further phase III trials investigating romidepsin in other indications are 
registered at ClinicalTrials.gov and at the EU Clinical Trials Register. Sev-
eral phase I and II trials are registered and on-going and investigate the effi-
no further studies 
included 
no price estimate yet 
available 
1 ongoing phase III trial 
with romidepsin as a 
comparator identified 
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cacy and safety of romidepsin in other indications (e.g. different types of T-
cell and B-cell lymphoma, chronic lymphocytic leukaemia or solid tumours 
such as lung, pancreatic or thyroid cancer, glioma and melanoma). 
9 Commentary  
Romidepsin for the treatment of relapsed or refractory PTCL patients after 
prior systemic chemotherapy is currently under review for marketing au-
thorisation in Europe. In 2004 and 2005, the US FDA and the EMA, respec-
tively, granted orphan drug designation for romidepsin for the treatment of 
PTCL and CTCL [12]. In the US, romidepsin was approved based on the 
fast track program for the treatment of CTCL and PTCL in 2009 and 2011, 
respectively [8]. Approval options like fast track status, accelerated approval 
and priority review were implemented by the FDA in order to provide more 
extensive and timely guidance to sponsors about the nature of the evidence 
that is needed to support approval and to speed reviews for drugs that are in-
tended for the treatment of serious or life-threatening conditions for which 
unmet needs for treatment exist [17]. 
Two pivotal studies including 178 patients overall led to the approval of ro-
midepsin in the US [7, 20]. These studies were two multicenter, single-arm 
phase II studies. The median age of the included patients was around 60 
years (range 20 to 84) and more than 50% of included patients were male. In 
both trials the most commonly represented subgroups were PTCL NOS 
(~55%), angioimmunoblastic T-cell lymphoma (15% to 21%) and ALCL 
ALK-negative (4% to 16%). All patients had received prior systemic therapy 
for the treatment of PTCL. In the NCT00426764 trial 38% patients were re-
fractory to their most recent therapy; the second trial did not provide such 
information. The primary efficacy endpoint in both studies was overall ORR 
consisting of CR/CRu and PR. ORR ranged from 25% to 38%. Median dura-
tion of ORR was 16.6 months (range <1.0 to 34) and 8.9 months (range 2 to 
74). The median duration of CR/CRu in the NCT00426764 trial is equal to 
the median duration of ORR and the median duration of PR in this trial is 
not reported. On the other hand the median duration of CR and PR is 29.7 
months (range 3-74) and 5.2 (2 to 23+), respectively, in the NCT00007345 
trial. Thus, it seems that duration of response is mainly driven by those pa-
tients achieving a CR/CRu. 
Within the NCT00426764 trial subgroup analyses were conducted according 
to baseline disease characteristics and prior therapeutic regimens, which ap-
peared not to have an impact on the ability of patients to respond to ro-
midepsin. Of patients refractory to their most recent prior therapy, 14 of 49 
patients (29%) responded to romidepsin therapy. 9 of these 14 patients 
achieved a CR/CRu [20].  
Due to the single-arm design of the studies neither time-to-event endpoints 
such as progression-free survival and overall survival nor observed adverse 
events can be reliably estimated [32]. A further limiting factor was the small 
sample size of both studies. Thus, efficacy evaluation in these two single-
arm trials was limited to response rates and duration of response, as these 
outcomes represent a direct treatment effect of the drug [33]. 
not yet approved in 
Europe 
2011: approval in the US 
for PTCL 
178 patients enrolled in 
two single-arm phase II 
studies 
 
most common PTCL 
subtypes: PTCL NOS, 
angioimmunoblastic T-
cell lymphoma, ALCL 
primary efficacy 
endpoint: ORR 
ORR: 25% to 38% 
median duration of 
ORR: 8.9 to 16.6 months 
29% of patients with 
refractory PTCL 
achieved ORR 
limitations inherent to 
single-arm design 
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According to the authors of the two studies romidepsin was well tolerated 
and the reported AEs were generally considered to be manageable and are 
similar to those observed in other clinical trials and reported for other 
HDAC inhibitors [7]. The most commonly reported AEs were nausea, infec-
tions (all types), fatigue, thrombocytopenia, vomiting and diarrhoea.  
In the study NCT00007345 a protocol amendment was conducted to exclude 
PTCL patients with significant cardiovascular disease and other patients at 
risk for sudden death due to a death observed in one patient with past car-
diac history and CR to romidepsin [7]. Overall, 2 patients in the 
NCT00007345 trial died while on study and 13 patients of the 178 patients 
died within 30 days the after last dose of the study drug; 7 due to progressive 
disease, and the remaining 5 died of infections or an event that occurred 
during infection.  
As described in chapter 5, currently no standard of care for the treatment of 
relapsed or refractory PTCL patients exists and enrolment onto a clinical 
trial is strongly recommended. Piekarz et al. 2011 [7] pointed out that due to 
several characteristics of T-cell lymphomas (rarity, aggressiveness and het-
erogeneity) it was not possible to fully establish standard therapies for this 
disease despite the fact that a number of different chemotherapeutics and 
biologic agents have shown activity in T-cell lymphomas. Within that con-
text, romidepsin might be an important therapeutic option for patients not 
responding to existing therapeutic regimens for the treatment of PTCL. On 
the other hand, with 40% of patients responding to romidepsin therapy and 
not yet knowing the exact mechanism of anti-tumour activity of romidepsin 
in T-cell lymphoma, one focus of future research has to be the clarification 
of the mechanism of action and the identification of patients that might 
benefit of romidepsin treatment in order to spare patients not likely to re-
spond to romidepsin unnecessary side effects. 
Since median duration of response to romidepsin is 29.7 months in patients 
with CR compared to 5.2 months for patients with PR, romidepsin should 
preferably be given to patients achieving a CR. Another question that re-
mains unanswered refers to the efficacy and safety of romidepsin given in 
combination with other anti-cancer drugs or whether it is most effective 
when given as a single-agent. 
Up to now, no RCT exists that compares different treatment options in re-
lapsed or refractory PTCL patients. As more and more chemotherapeutic 
and biologic agents are currently investigated and become available in this 
indication, RCTs to compare their efficacy and safety in order to enable the 
establishment of treatment recommendations based on direct head-to-head 
comparison data are necessary. Currently, there is one phase III RCT ongo-
ing that evaluates the efficacy of the new agent alisernib to single-agent 
therapy chosen by the investigator. One of the possible comparators is ro-
midepsin in countries where it is permitted for use. 
 
overall romidepsin was 
considered to be well 
tolerated 
patients at risk for 
sudden death were 
excluded from the study 
currently no standard of 
care exists for relapsed 
or refractory PTCL = 
unmet medical need 
 
romidepsin might be an 
important treatment 
option in this indication 
 
mechanism of action 
not yet clear 
need for comparison of 
new and existing 
therapy options to 
establish treatment 
recommendations 
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